S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
CVE:RX

BioSyent Stock Forecast, Price & News

C$7.25
0.00 (0.00 %)
(As of 09/27/2021 03:41 PM ET)
Add
Compare
Today's Range
C$7.01
C$7.25
50-Day Range
C$7.20
C$8.30
52-Week Range
C$6.59
C$9.59
Volume2,660 shs
Average Volume7,131 shs
Market CapitalizationC$91.81 million
P/E Ratio21.64
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.


BioSyent logo

About BioSyent

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
C$26.21 million
Cash Flow
C$1.97 per share
Book Value
C$2.27 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
C$91.81 million
Next Earnings Date
11/25/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.20 out of 5 stars

Analyst Opinion: 1.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












BioSyent (CVE:RX) Frequently Asked Questions

Is BioSyent a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSyent in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BioSyent stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RX, but not buy additional shares or sell existing shares.
View analyst ratings for BioSyent
or view top-rated stocks.

What stocks does MarketBeat like better than BioSyent?

Wall Street analysts have given BioSyent a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioSyent wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioSyent's next earnings date?

BioSyent is scheduled to release its next quarterly earnings announcement on Thursday, November 25th 2021.
View our earnings forecast for BioSyent
.

How were BioSyent's earnings last quarter?

BioSyent Inc. (CVE:RX) posted its quarterly earnings results on Thursday, May, 25th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. The firm had revenue of $3.82 million for the quarter, compared to analysts' expectations of $4.80 million.
View BioSyent's earnings history
.

How has BioSyent's stock price been impacted by COVID-19 (Coronavirus)?

BioSyent's stock was trading at C$4.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RX shares have increased by 66.7% and is now trading at C$7.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RX?

2 analysts have issued 12 month price targets for BioSyent's stock. Their forecasts range from C$7.50 to C$7.50. On average, they expect BioSyent's stock price to reach C$7.50 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for BioSyent
or view top-rated stocks among Wall Street analysts.

Who are BioSyent's key executives?

BioSyent's management team includes the following people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Robert J. March, VP of Fin. & CFO
  • Mr. Joost van der Mark, VP of Corp. Devel.
  • Ms. Neelu Atwal, Director of HR
  • Mr. Alfred D'Souza, Advisor

What other stocks do shareholders of BioSyent own?

What is BioSyent's stock symbol?

BioSyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How do I buy shares of BioSyent?

Shares of RX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BioSyent's stock price today?

One share of RX stock can currently be purchased for approximately C$7.25.

How much money does BioSyent make?

BioSyent has a market capitalization of C$91.81 million and generates C$26.21 million in revenue each year.

What is BioSyent's official website?

The official website for BioSyent is www.biosyent.com.

Where are BioSyent's headquarters?

How can I contact BioSyent?

BioSyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.